Abstract | BACKGROUND: METHODS: RESULTS: Median follow-up was 58.5 months in the continuous tafamidis group (n=176) and 57.1 months in the placebo to tafamidis group (n=177). There were 79 (44.9%) deaths with continuous tafamidis and 111 (62.7%) with placebo to tafamidis (hazard ratio, 0.59 [95% CI, 0.44-0.79]; P<0.001). Mortality was also reduced in the continuous tafamidis (versus placebo to tafamidis) subgroups of: variant transthyretin amyloidosis (0.57 [0.33-0.99]; P=0.05) and wild-type transthyretin amyloidosis (0.61 [0.43-0.87]; P=0.006); and baseline New York Heart Association class I and II (0.56 [0.38-0.82]; P=0.003) and class III (0.65 [0.41-1.01]; P=0.06). CONCLUSIONS: In the LTE, patients initially treated with tafamidis in ATTR-ACT had substantially better survival than those first treated with placebo, highlighting the importance of early diagnosis and treatment in transthyretin amyloid cardiomyopathy. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01994889 and NCT02791230.
|
Authors | Perry Elliott, Brian M Drachman, Stephen S Gottlieb, James E Hoffman, Scott L Hummel, Daniel J Lenihan, Ben Ebede, Balarama Gundapaneni, Benjamin Li, Marla B Sultan, Sanjiv J Shah |
Journal | Circulation. Heart failure
(Circ Heart Fail)
Vol. 15
Issue 1
Pg. e008193
(01 2022)
ISSN: 1941-3297 [Electronic] United States |
PMID | 34923848
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzoxazoles
- Prealbumin
- tafamidis
|
Topics |
- Aged
- Aged, 80 and over
- Amyloid Neuropathies, Familial
(complications, drug therapy, mortality)
- Benzoxazoles
(pharmacology)
- Cardiomyopathies
(complications, drug therapy, mortality)
- Female
- Heart Failure
(complications, drug therapy, mortality)
- Hospitalization
(statistics & numerical data)
- Humans
- Male
- Middle Aged
- Prealbumin
(pharmacology)
- Proportional Hazards Models
- Time
|